A series of cardiometabolic-related news items has been observed from Altimmune, AstraZeneca, Insilico Medicine, and Lilly. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from Novo Nordisk, AstraZeneca, Boehringer Ingelheim, and Abbott/Google. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from AstraZeneca, Luna Diabetes, Ascletis Pharma, Ionis Pharmaceuticals, Lexicon Pharmaceuticals, and Veru. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from AstraZeneca, Boehringer Ingelheim, MiniMed, Corxel Pharmaceuticals, and Galectin Therapeutics. Below, FENIX provides highlights and insights for the respective news items.
AstraZeneca hosted an investor event in conjunction with the final day of ADA 2026 and provided updates across its obesity pipeline, including its late-stage development plans for elecoglipron (QD oral small molecule GLP-1RA). Prior to the call, full results from the asset’s Ph2b VISTA and SOLSTICE studies were presented at the ADA conference and simultaneously published in The Lancet (view VISTA publication; view SOLSTICE publication). For additional insight into AZ’s position in the obesity market, as part of the ongoing Spotlight Series, FENIX conducted a deep dive analysis (view AZ Obesity Spotlight). Below, FENIX provides highlights and insights from the data readout and investor call (slide link unavailable).
With ADA 2026 approaching (June 5-8; New Orleans, LA), FENIX has compiled a shortlist of key sessions and presentations that warrant close attention across the meeting. While ADA brings new data and fresh perspectives across the cardiometabolic space each year, the list below focuses exclusively on the sessions with potential to shape this year’s conference narrative and ultimately, have an outsized impact on the field for years to come.
A series of cardiometabolic-related news items has been observed from AstraZeneca, AbbVie, Regeneron, Ionis, GSK, and Zealand Pharma/Roche. Below, FENIX provides highlights and insights for the respective news items.
In the tenth installment of FENIX’s Obesity Spotlight Series, FENIX has conducted a deep dive analysis of AstraZeneca’s current position in the obesity market. The analysis includes insights into AZ’s strategy to replace Farxiga revenue and how it is seemingly following Lilly’s obesity playbook.
A series of cardiometabolic-related news items has been observed from Madrigal Pharmaceuticals, Novo Nordisk, Eccogene, Ascletis Pharma, Cascade Pharmaceuticals, and Hoth Therapeutics. Below, FENIX provides highlights and insights for the respective news items.
A series of cardiometabolic-related news items has been observed from AstraZeneca, Kailera Therapeutics/Hengrui Pharma, Pfizer, Novo Nordisk, and Sava Technologies. Below, FENIX provides highlights and insights on the respective news items.